EpiTherapeutics is developing novel innovative cancer drugs based on the world leading research in epigenetics conducted by Professor Kristian Helin and his group at Biotech Research & Innovation Centre (BRIC) at University of Copenhagen.

EpiTherapeutics' development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. Subsequent developments may identify other potential clinical indications outside oncology.

EpiTherapeutics has a strong investor base and recently founding investors Novo A/S and SEED Capital Denmark was joined by Lundbeckfond Ventures, Astellas Venture Management and Merck Serono Ventures
2009 © Epitherapeutics ApS. All rights reserved.